Biologic Reduces Impact of Genital Psoriasis on Sexual Activity

02/23/2018
psoriasis

Ixekizumab (Taltz) significantly improved sexual activity among patients with genital psoriasis (GP), reported Jennifer Cather, MD, and colleagues at the 2018 American Academy of Dermatology Annual Meeting.

Their study evaluated the impact of ixekizumab on sexual activity among 149 participants with moderate to severe GP. Following an initial dose of placebo or 160 mg of ixekizumab, participants were randomly assigned to receive either placebo or 80 mg of ixekizumab every 2 weeks. The Genital Psoriasis Sexual Impact Scale (GPSIS), which included avoidance and impact subscales, the Sexual Frequency Questionnaire (SFQ) item 2, and the Dermatology Quality of Life (DLQI) item 9 were used to measure patient-reported outcomes.

The proportion of patients reporting that their frequency of sexual activity was rarely or never limited by GP on the SFQ item 2 (0/1), was rarely or never impacted by GP on the GPSIS-Avoidance (1/2), and whose GP symptom worsening after sexual activity was very low/none at all or low on the GPSIS-Impact (1/2) were assessed as the main outcomes. In addition, the percentage of participants who reported little or no impairment of sexual activity on the DLQI item 9 (0/1) was examined.

After 12 weeks of treatment, ixekizumab was found to reduce the impact of GP on sexual activity compared with placebo. Participants who received ixekizumab were more likely to reported 0/1 on the SFP item 2 (78.4 vs 21.4%, respectively) 1/2 on the GPSIS-Avoidance (76.7% vs 25.7%), and 0/1 on the DLQI item 9 (92% vs 56.8%) compared with placebo. Responses to treatment with ixekizumab were noticeable as early as week 1 on the SFQ item 2, week 2 on the DLQI item 9, and week 4 on the GPSIS-Avoidance.

In addition, 85.7% of participants who received ixekizumab reported a reduce impact of sexual activity on the GPSIS-Impact compared with 52.9% of those who received placebo.

“During 12 weeks of treatment, [ixekizumab] resulted in rapid and significant decrease in the impact of GP on sexual activity, including how often GP limited sexual frequency among patients with moderate to severe GP,” the researchers concluded.

—Melissa Weiss

Reference

Cather J, Meeuwis K, Burge R, Bleakman AP, Lin CY, Ryan C. Ixekizumab provides greater improvement verse placebo on the impact of genital psoriasis on sexual activity for patients with moderate to severe genital psoriasis in a randomized, double-blind phase 3b clinical trial. Presented at: American Academy of Dermatology Annual Meeting; February 16-20, 2018; San Diego, CA.